BioTuesdays

Author - Leonard Zehr

Auris Medical
Markets

Roth starts Auris Medical at buy

Roth Capital Partners initiated coverage of Auris Medical Holding (NASDAQ:EARS), a Swiss biopharmaceutical company developing therapeutics that address unmet medical needs in otology, with a “buy” rating and price...

April 13, 2017
IntelGenx Logo
Developments

IntelGenx, Tetra to develop Dronabinol XL tablet

IntelGenx (OTCQX:IGXT; TSXV:IGX) and Tetra Bio-Pharma (CSE:TBP; OTC:GRPOF) signed a definitive agreement to develop and commercialize a drug product containing the cannabinoid, Dronabinol, for the management of anorexia...

April 3, 2017
Calithera Biosciences
Markets

Leerink resumes coverage of Calithera at OP

Leerink resumed coverage of Calithera Biosciences (NASDAQ:CALA) with an “outperform” rating and a $16 price target, saying the company is well positioned to execute with multiple sources of upside. The stock closed at...

April 3, 2017
3D Signatures
Developments

3DS completes assay validation for HL

3D Signatures (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0) has successfully completed internal analytical assay validation for its Hodgkin’s lymphoma (HL) test (Telo-HL) according to FDA guidelines. Assay validation of Telo...

March 29, 2017
Vital Therapies Logo
Markets

Vital Therapies prices $35-million stock offering

Vital Therapies (NASDAQ:VTL) has priced a public offering of 8,750,000 newly issued common shares at a price of $4 each for gross proceeds of approximately $35-million. Vital also granted the underwriters a 30-day...

March 22, 2017
Checkpoint Therapeutics
Markets

Ladenburg starts Checkpoint Therapeutics at buy

Ladenburg Thalmann initiated coverage of Checkpoint Therapeutics (OTCQX:CKPT) with a “buy” rating and $20 price target. The stock closed at $13 on March 21. CKPT focuses on combination treatments for solid tumors based...

March 22, 2017